中心性肥胖与高血压:谁是射血分数保留心衰的主要驱动因素?
该综述指出,中心性肥胖是HFpEF发生和进展的主要驱动因素,其重要性超过高血压;人群中中心性肥胖在HFpEF临床显现前多年即出现,且见于>80%至90%的已确诊HFpEF患者;减重手术或肠促胰岛素类药物可降低心衰住院风险40%至60%,而降压治疗对HFpEF事件风险的降低幅度有限。
要点
- 中心性肥胖在HFpEF患者中普遍存在,且与血流动力学和临床严重程度密切相关。
- 孟德尔随机化研究显示HFpEF与肥胖的关联强于高血压。
- 减重干预可显著降低心衰住院风险,而降压对HFpEF事件风险降低有限。
核心结论
- 当前证据总体表明,中心性肥胖比高血压更重要地决定HFpEF的演变和进展。
- 过量脂肪堆积在HFpEF中的作用被严重低估,部分因依赖BMI而非腰高比识别脂肪增多。
研究设计与样本
- 综述性文章,系统评估高血压与肥胖在HFpEF发生和进展中的相对重要性。
主要发现
- 在普通人群中,中心性肥胖和内脏脂肪变化在HFpEF临床显现前数年即可观察到。
- 中心性肥胖存在于>80%至90%的已确诊HFpEF患者中,肥胖程度与HFpEF的血流动力学和临床严重程度强相关。
- 减重手术或肠促胰岛素类药物治疗使心衰住院风险降低40%至60%。
- 孟德尔随机化研究中,HFpEF与肥胖的关联比与高血压的关联更强。
- 在已确诊HFpEF患者的试验中,药物降低收缩压3至7 mm Hg仅使心衰事件风险降低5%至18%,且获益幅度与基线收缩压升高程度或降压幅度无关。
关键数值与推荐
- 已确诊HFpEF患者中中心性肥胖的患病率为>80%至90%。
- 减重手术或肠促胰岛素类药物报告的心衰住院风险降低幅度为40%至60%。
- 在HFpEF试验中,药物降低收缩压3至7 mm Hg对应的心衰事件风险降低为5%至18%。
临床怎么用
- 临床评估HFpEF风险时应重视中心性肥胖指标(如腰高比)而非仅依赖BMI。
- 对HFpEF患者,减轻过量脂肪堆积可能比单纯降压更有效地改善预后。
- 降压治疗在合并肥胖的HFpEF患者中可能无法充分缓解左室收缩舒张功能及血管僵硬。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 2 most prevalent risk factors for the development of heart failure and a preserved ejection fraction (HFpEF) are hypertension and obesity, but their relative importance in driving the evolution and progression of HFpEF has not been critically evaluated. The role of excess adiposity in HFpEF has been substantially underappreciated, largely because of reliance on body mass index (rather than waist-to-height ratio) to identify an expanded fat mass and on a meaningful elevation of natriuretic peptides to identify HFpEF. In the general population, changes in central obesity and visceral adiposity are observed years before HFpEF becomes clinically manifest, and central obesity is present in >80% to 90% of patients with established HFpEF, with the degree of adiposity being strongly related to the hemodynamic and clinical severity of HFpEF. Therapeutic amelioration of excess adiposity by bariatric surgery or incretin-based drugs appears to have substantial effects on the evolution and progression of HFpEF, with reported reductions of 40% to 60% in the risk of heart failure hospitalizations. Hypertension also increases the risk of heart failure, but in Mendelian randomization studies, HFpEF is more strongly linked to obesity than to hypertension. Furthermore, the available evidence from clinical trials does not support a consistent link between blood pressure lowering and a reduced risk of HFpEF, particularly in patients with coexisting obesity. Although a history of hypertension is exceptionally prevalent among patients with established HFpEF, in trials of patients with established HFpEF, drugs that lowered systolic blood pressure by 3 to 7 mm Hg yielded a heart failure event risk reduction of only 5% to 18%. Furthermore, the magnitude of the observed benefit on heart failure events was not related to the elevation of baseline systolic blood pressure or the magnitude of the drug-related decreases in blood pressure. Adiposity causes hypertension, and if excess adiposity is not alleviated, blood pressure lowering with many antihypertensive drugs may not be able to alleviate left ventricular systolic and diastolic and vascular stiffness. Taken together, the totality of evidence suggests that-in the current era-central adiposity appears to be more important than hypertension as a determinant of the evolution and progression of HFpEF.
引用
- Packer, Butler, Lam, et al. Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction? J Am Coll Cardiol. 2025. PMID: 41031977. doi:10.1016/j.jacc.2025.08.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。